Naveris
Waltham, US · Founded 2017 · Delaware corporation · 3 known investors
Find your way into Naveris
849 people in our graph share verified history with the Naveris team — schools, employers, funds. One of them is your warm intro.
Kyle Dohertyunlockedknows James McNally · together at Harvard Business School (overlapped)
×3knows the team · via Morgan Stanley Investment Banking
×6knows the team · via Harvard Business School
×2knows the team · via Princeton University
Naveris develops and commercializes liquid biopsy tests for the early detection and monitoring of HPV-associated cancers, particularly head and neck and anal cancers. The company's flagship NavDx test uses proprietary technology to detect tumor tissue-modified viral HPV DNA in blood plasma, offering high sensitivity and specificity for cancer surveillance.
Founders & leadership
JM
James McNallyinChief Executive Officer2023–2026James McNally is an executive with extensive experience in healthcare technology, including commercial strategy, product launches, business development, fundraising, and sales management across diagnostics and medical device sectors. He has led medical device development, M&A transactions, and IPO processes for venture-backed companies.
PG
Piyush GuptaNamed on SEC filing
Board
AS
Anne StoneBoard director
FC
Francis CrispinoBoard director
PG
Philip Grahame HaydonBoard director
Investors · 3
Also in the syndicate · 1
BrightEdge
Funding
SEC filings, press & company announcements$67M disclosed across 4 of 5 rounds · 2019–2024
- $33.4MSeries ASep 2022 · 3 sources
Gurnet Point Capital (lead), BrightEdge, TechU Ventures
Source ↗
▶$17.5MraisedJul 2024 · 5 investors · BiotechnologyRule 506(b)
▶$17.5MraisedJul 2024 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James McNallyExecutive Officer, Director
- Anne StoneDirector
- Francis CrispinoDirector
- Piyush GuptaExecutive Officer, Director
- Offering amount
- $27.2M
- Amount sold
- $17.5M
- Sales commissions
- $1.8M
- Placement agents
- Cowen and Company, LLC
- First sale
- Jun 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$15.4MraisedMar 2020 · 21 investors · BiotechnologyRule 506(b)
▶$15.4MraisedMar 2020 · 21 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Piyush GuptaExecutive Officer, Director
- Philip StephensExecutive Officer
- Barry BergerDirector
- Sophie KornowskiDirector
- Offering amount
- $17M
- Amount sold
- $15.4M
- First sale
- Feb 2020
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$650KraisedSep 2019 · 3 investors · Other TechnologyRule 506(b)
▶$650KraisedSep 2019 · 3 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Philip Grahame HaydonDirector
- Piyush GuptaExecutive Officer, Director
- Offering amount
- $3M
- Amount sold
- $650K
- First sale
- Sep 2019
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlap
Labcorp26 shared keywordsLabCorp provides diagnostic testing services and clinical trial recruitment solutions that connect patient insights to drug development for healthcare providers.
Alumis25 shared keywordsAlumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases. It focuses on small-molecule drug discovery and development in immunology and inflammation.
Companies competing with Naveris for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Naveris do?
- Naveris develops and commercializes liquid biopsy tests for the early detection and monitoring of HPV-associated cancers, particularly head and neck and anal cancers. The company's flagship NavDx test uses proprietary technology to detect tumor tissue-modified viral HPV DNA in blood plasma, offering high sensitivity and specificity for cancer surveillance.
- Who are Naveris's investors?
- Naveris's investors include Gurnet Point Capital, TechU Ventures.
- How much funding has Naveris raised?
- Naveris has disclosed $67M raised across 4 of its 5 known rounds.
- Where is Naveris headquartered?
- Naveris is headquartered in Waltham, US.